Description: Tibet AIM Pharm. Inc. engages in the research and development of medical products in China. The company's products include Miglitol tablets for diabetes; Gualoupi injection for coronary disease; Oxytocin injection for gynecology and obstetrics; NalMefene injection for various acute poisoning, such as alcohol, organic phosphor, CO, sedative-hypnotic, opioid substance, serious infection, shock, fainting, and brain; Carbetocin injections; and Hongjin Xiaojie tablets and Aceclofenac Enteric-Coated tablets, as well as for the treatment of antibiotic, antiallergic, and digestive system. Tibet AIM Pharm. Inc. was founded in 2003 and is headquartered in Beijing, China.
Home Page: www.emyy.cn
Building C, Yingdu Building
Beijing,
100086
China
Phone:
86 10 5873 1516
Officers
| Name | Title |
|---|---|
| Mr. Ke Xu | MD, Financial Director & Director |
| Mr. Hang Liu | Deputy Gen. Mang. |
| Mr. Yu Zhang | Deputy GM & Non-Independent Director |
| Ms. Qianjin Li | Deputy GM & Board Sec. |
Exchange: SHE
Country: CN
Currency: Renminbi (¥)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 46 |
| Price-to-Book MRQ: | 3.2095 |
| Price-to-Sales TTM: | 2.9542 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 430 |